Kamisha L. Johnson-Davis
No Rating Available
(Learn About Our Rating System)

Kamisha L. Johnson-Davis, PhD, Executive MBA

Languages spoken: English

  • Dr. Johnson-Davis is a Professor (Clinical) at the University of Utah in the Department of Pathology and Medical Director for Clinical Toxicology at ARUP Laboratories. She received her B.S. degree in Biochemistry from the University of California, Riverside, a Ph.D. in Pharmacology, and an Executive MBA from the University of Utah. She was a postdoctoral research associate at the Center for Human Toxicology, and she completed a postdoctoral fellowship in clinical chemistry at the University of Utah, Department of Pathology. Dr. Johnson-Davis is board-certified in Clinical Chemistry and Toxicological Chemistry. She is a Diplomate of the American Board of Clinical Chemistry and a Fellow of the Association for Diagnostics & Laboratory Medicine.

    Specialties

    • Pathology, Clinical

    Board Certification

    American Board of Clinical Chemistry (Sub: Clinical Chemistry)
    American Board of Clinical Chemistry (Sub: Toxicological Chemistry)

  • Dr. Johnson-Davis is a Professor (Clinical) at the University of Utah in the Department of Pathology and Medical Director for Clinical Toxicology at ARUP Laboratories. She received her B.S. degree in Biochemistry from the University of California, Riverside, a Ph.D. in Pharmacology, and an Executive MBA from the University of Utah. She was a postdoctoral research associate at the Center for Human Toxicology, and she completed a postdoctoral fellowship in clinical chemistry at the University of Utah, Department of Pathology. Dr. Johnson-Davis is board-certified in Clinical Chemistry and Toxicological Chemistry. She is a Diplomate of the American Board of Clinical Chemistry and a Fellow of the Association for Diagnostics & Laboratory Medicine.

    Board Certification and Academic Information

    Academic Departments Pathology -Professor (Clinical)
    Board Certification
    American Board of Clinical Chemistry (Sub: Clinical Chemistry)
    American Board of Clinical Chemistry (Sub: Toxicological Chemistry)

    Education history

    Professional Other Master of Business Administration - University of Utah EMBA
    Postdoctoral Fellowship Clinical Chemistry Fellowship program, Certificate #102 - University of Utah, Department of Pathology Postdoctoral Training
    Postdoctoral Fellowship Human Toxicology - University of Utah, Center for Human Toxicology, Research Associate Postdoctoral Fellow
    Doctoral Training Pharmacology - University of Utah, Department of Pharmacology &Toxicology Ph.D.
    Undergraduate Biochemistry - University of California, Riverside, Department of Biochemistry B.S.

    Selected Publications

    Journal Article

    1. Mathewson NJ, Okoye NC, Nelson HA, Pandya V, Moore C, Johnson-Davis KL (2024). Beyond the baseline: quantification of two phosphatidylethanol homologues in whole blood by LC-MS-MS and retrospective data analysis from a National Reference Laboratory. J Anal Toxicol, 49(3), 191-200. (Read full article)
    2. Bithi N, Ricks D, Walker BS, Law C, Johnson-Davis KL (2024). Method validation of an inductively coupled plasma mass spectrometry (ICP-MS) assay for the analysis of magnesium, copper and zinc in red blood cells. J Mass Spectrom Adv Clin Lab, 34, 21-27. (Read full article)
    3. Bithi N, Ricks D, Walker BS, Law C, Johnson-Davis KL (2024). Method validation of an inductively coupled plasma mass spectrometry (ICP-MS) assay for the analysis of magnesium, copper and zinc in red blood cells. J Mass Spectrom Adv Clin Lab, 34, 21-27. (Read full article)
    4. Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, Vinks S, Wieland E, Bornemann-Kolatzki K, Brunet M, de Winter B, Dieterlen MT, Elens L, Ito T, Johnson-Davis K, Kunicki PK, Lawson R, Lloberas N, Marquet P, Millan O, Mizuno T, Moes DJAR, Noceti O, Oellerich M, Pattanaik S, Pawinski T, Seger C, van Schaik R, Venkataramanan R, Walson P, Woillard JB, Langman LJ (2024). Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. (Read full article)
    5. Snozek CLH, Yee CI, Bryksin J, Dahal R, Gerson B, Gherasim C, Hauff KD, Heger N, Huestis MA, Johnson-Davis KL, Knezevic CE, Love SA, Melanson SEF, Noguez JH, Pikulski M, Roper S, Tyagi M, Warrington JS, Yang HS, Yang YK (2024). Assessing knowledge gaps and educational needs in urine drug test interpretation among health care professionals. Am J Clin Pathol. (Read full article)
    6. Baryeh K, Zhou R, Brown E, McMillin GA, Krasowski MD, Johnson-Davis KL (2024). Retrospective Data Analysis Reveals Unusual Metabolism Pattern of Ethanol in Pediatrics as Compared to Adult and Geriatric Populations. J Appl Lab Med. (Read full article)
    7. McMillin GA, Morad AW, Boyd JM, Johnson-Davis KL, Metz TD, Smid MC, Krasowski MD (2024). Biological Testing and Interpretation of Laboratory Results Associated with Detecting Newborns with Substance Exposure. Clin Chem, 70(7), 934-947. (Read full article)
    8. Johnson-Davis KL, Ly D (2023). Quantification of Olanzapine by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Methods Mol Biol, 2737, 347-357. (Read full article)
    9. Johnson-Davis KL, Thomas RL (2023). Quantification of Oxcarbazepine Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Methods Mol Biol, 2737, 387-395. (Read full article)
    10. Shaaban S, Walker BS, Ji Y, Johnson-Davis K (2025). TPMT and NUDT15 genotyping, TPMT enzyme activity and metabolite determination for thiopurines therapy: a reference laboratory experience. Pharmacogenomics, 25(16-18), 679-688. (Read full article)
    11. Pandya V, Wilker C, Johnson-Davis KL (2022). Longitudinal trends in meconium drug detection in 46 US states between the years 2015 and 2020. J Anal Toxicol, 47(6), 495-503. (Read full article)
    12. Okoye NC, Zuromski LM, Johnson-Davis KL (2023). Trends in Blood Lead Levels Quantified by ICP-MS: A Reference Laboratory Retrospective Study. J Appl Lab Med. (Read full article)
    13. Lemaitre F, Budde K, Van Gelder T, Bergan S, Lawson R, Noceti O, Venkataramanan R, Elens L, Moes DJAR, Hesselink DA, Pawinski T, Johnson-Davis KL, De Winter BCM, Pattanaik S, Brunet M, Masuda S, Langman LJ (2022). Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19. Ther Drug Monit, 45(2), 191-199. (Read full article)
    14. Smith K, Johnson-Davis KL, Shahrokh K (2022). A New Broad-Spectrum Drug Screen for 127 Analytes by LC-MS/MS. J Appl Lab Med, 8(2), 240-250. (Read full article)
    15. Bajaj AO, Parker R, Farnsworth C, Law C, Johnson-Davis KL (2023). Method validation of multi-element panel in whole blood by inductively coupled plasma mass spectrometry (ICP-MS). J Mass Spectrom Adv Clin Lab, 27, 33-39. (Read full article)
    16. Bajaj AO, Parker R, Farnsworth C, Law C, Johnson-Davis KL (2022). Method validation of multi-element panel in whole blood by inductively coupled plasma mass spectrometry (ICP-MS). J Mass Spectrom Adv Clin Lab, 27, 33-39. (Read full article)
    17. Bajaj AO, Ly D, Johnson-Davis KL (2022). Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS. J Mass Spectrom Adv Clin Lab, 24, 100-106. (Read full article)
    18. Bajaj AO, Ly D, Johnson-Davis KL (2022). Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS. J Mass Spectrom Adv Clin Lab, 24, 100-106. (Read full article)
    19. Bajaj AO, Kushnir MM, Kish-Trier E, Law RN, Zuromski LM, Molinelli AR, McMillin GA, Johnson-Davis KL (2022). LC–MS/MS Method for Measurement of Thiopurine Nucleotides (TN) in Erythrocytes and Association of TN Concentrations With TPMT Enzyme Activity. Front Pharmacol, 13. (Read full article)
    20. Bajaj AO, Kushnir MM, Kish-Trier E, Law RN, Zuromski LM, Molinelli AR, McMillin GA, Johnson-Davis KL (2022). LC-MS/MS Method for Measurement of Thiopurine Nucleotides (TN) in Erythrocytes and Association of TN Concentrations With TPMT Enzyme Activity. Front Pharmacol, 13, 836812. (Read full article)
    21. Hunsaker JJH, Laulu SL, LaGrave D, Murphy W, Reichman HA, Snow TM, McMillin GA, Johnson-Davis KL, Genzen JR (2021). Tobacco and Cannabis Use During Pregnancy. Am J Clin Pathol, 157(1), 146-152. (Read full article)
    22. Clarke WA, Salyer B, Hussey C, Gardiner J, Johnson-Davis K, Milone MC (2021). Multi-Site Evaluation of Immunoassays for Antipsychotic Drug Measurement in Clinical Samples. J Appl Lab Med, 6(6), 1541-1550. (Read full article)
    23. Okoye NC, Greene DN, Johnson-Davis KL (2021). Is the Confirmatory Test Always Right? Sometimes Immunoassays Know What They Are Talking About. J Appl Lab Med. (Read full article)
    24. Kroner GM, Thomas RL, Johnson-Davis KL (2020). Retrospective Analysis of Pediatric and Adult Populations Using an LC-MS/MS Method for Oxcarbazepine/Eslicarbazepine Metabolite. J Appl Lab Med, 6(3), 637-644. (Read full article)
    25. Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S, Millan O, Mizuno T, Moes DJAR, Oellerich M, Picard N, Salzmann L, Tnshoff B, van Schaik RHN, Vethe NT, Vinks AA, Wallemacq P, sberg A, Langman LJ (2020). Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit, 43(2), 150-200. (Read full article)
    26. McMillin GA, Johnson-Davis KL, Kelly BN, Scott B, Yang YK (2020). Impact of the Opioid Epidemic on Drug Testing. Ther Drug Monit, 43(1), 14-24. (Read full article)
    27. Yang YK, Johnson-Davis KL, Kelly BN, McMillin GA (2020). Demand for Interpretation of a Urine Drug Testing Panel Reflects the Changing Landscape of Clinical Needs; Opportunities for the Laboratory to Provide Added Clinical Value. J Appl Lab Med, 5(5), 858-868. (Read full article)
    28. Johnson-Davis KL, Farnsworth C, Law C, Parker R (2020). Method validation for a multi-element panel in serum by inductively coupled plasma mass spectrometry (ICP-MS). Clin Biochem, 82, 90-98. (Read full article)
    29. Kroner GM, Johnson-Davis KL, Doyle K, McMillin GA (2019). Cannabinol (CBN) Cross-Reacts with Two Urine Immunoassays Designed to Detect Tetrahydrocannabinol (THC) Metabolite. J Appl Lab Med, 5(3), 569-574. (Read full article)
    30. Johnson-Davis KL, Doyle K (2019). Therapeutic Drug Monitoring in Pregnant Patients. Ther Drug Monit, 42(2), 172-180. (Read full article)
    31. Gruzdys V, Merrigan SD, Johnson-Davis KL (2019). Feasibility of Immunosuppressant Drug Monitoring by a Microsampling Device. J Appl Lab Med, 4(2), 241-246. (Read full article)
    32. Snozek CLH, Corey RL, Buras MR, Johnson-Davis KL (2018). False-Positive Serum Cocaine Screening Results in Patients Undergoing Evaluation for Renal Transplant. J Anal Toxicol, 43(7), 587-590. (Read full article)
    33. Brunet M, van Gelder T, sberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Milln O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S (2019). Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit, 41(3), 261-307. (Read full article)
    34. Merrigan SD, Johnson-Davis KL (2018). A 6 Second Analytical Method for Quantitation of Tacrolimus in Whole Blood by Use of Laser Diode Thermal Desorption Tandem Mass Spectrometry. J Appl Lab Med, 3(6), 965-973. (Read full article)
    35. Wiencek JR, Gehrie EA, Keiser AM, Szklarski PC, Johnson-Davis KL, Booth GS (2019). Detection of Nicotine and Nicotine Metabolites in Units of Banked Blood. Am J Clin Pathol, 151(5), 516-521. (Read full article)
    36. Wu F, Melis R, McMillin GA, Johnson-Davis KL (2018). Retrospective Data Analysis of the Influence of Age and Sex on TPMT Activity and Its Phenotype-Genotype Correlation. J Appl Lab Med, 3(5), 827-838. (Read full article)
    37. Smith KA, Merrigan SD, Johnson-Davis KL (2018). Selecting a Structural Analog as an Internal Standard for the Quantification of 6-Methylmercaptopurine by LC-MS/MS. J Appl Lab Med, 3(3), 384-396. (Read full article)
    38. Johnson-Davis KL (2017). Opiate & Benzodiazepine Confirmations: To Hydrolyze or Not to Hydrolyze is the Question. J Appl Lab Med, 2(4), 564-572. (Read full article)
    39. Merrigan SD, Kish-Trier E, Seegmiller JC, Johnson-Davis KL (2017). LC-MS/MS method for quantitation of mycophenolic acid, mycophenolic acid acyl-glucuronide, and 7-O-mycophenolic acid glucuronide in serum. Clin Mass Spectrom, 3, 41-48. (Read full article)
    40. Merrigan SD, Kish-Trier E, Seegmiller JC, Johnson-Davis KL (2017). LC–MS/MS method for quantitation of mycophenolic acid, mycophenolic acid acyl-glucuronide, and 7-O-mycophenolic acid glucuronide in serum. Clin Mass Spectrom, 3, 41-48. (Read full article)
    41. Rule GS, Rockwood AL, Johnson-Davis KL (2015). LC-MS/MS Method for Determination of Teriflunomide, Over a 40,000-Fold Dynamic Range Using Overlapping Calibrators. Ther Drug Monit, 37(4), 472-8. (Read full article)
    42. Schniedewind B, Niederlechner S, Galinkin JL, Johnson-Davis KL, Christians U, Meyer EJ (2015). Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study. Ther Drug Monit, 37(3), 296-303. (Read full article)
    43. Marin SJ, Sawyer JC, He X, Johnson-Davis KL (2015). Comparison of drug detection by three quadrupole time-of-flight mass spectrometry platforms. J Anal Toxicol, 39(2), 89-95. (Read full article)
    44. McMillin GA, Marin SJ, Johnson-Davis KL, Lawlor BG, Strathmann FG (2015). A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. Am J Clin Pathol, 143(2), 234-40. (Read full article)
    45. Petrides AK, Moskowitz J, Johnson-Davis KL, Jannetto PJ, Langman LJ, Clarke W, Marzinke MA (2014). The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum. Clin Biochem, 47(15), 73-9. (Read full article)
    46. Lin CN, Juenke JM, Johnson-Davis KL (2014). Method validation of a tricyclic antidepressant drug panel in urine by UPLC-MS/MS. Ann Clin Lab Sci, 44(4), 431-6. (Read full article)
    47. McMillin GA, Slawson MH, Marin SJ, Johnson-Davis KL (2013). Demystifying analytical approaches for urine drug testing to evaluate medication adherence in chronic pain management. J Pain Palliat Care Pharmacother, 27(4), 322-39. (Read full article)
    48. Johnson-Davis KL, Thompson CD, Clark CJ, McMillin GA, Lehman CM (2012). Method comparison of the Ortho Vitros Fusion 5,1 chemistry analyzer and the Roche COBAS Integra 400 for urine drug screen testing in the emergency department. J Anal Toxicol, 36(5), 345-8. (Read full article)
    49. McMillin GA, Johnson-Davis K, Dasgupta A (2012). Analytical performance of a new liquid chromatography/tandem mass spectrometric method for determination of everolimus concentrations in whole blood. Ther Drug Monit, 34(2), 222-6. (Read full article)
    50. McMillin GA, Johnson-Davis K, Dasgupta A (2012). Analytical performance of a new liquid chromatography/tandem mass spectrometric method for determination of everolimus concentrations in whole blood (Therapeutic Drug Monitoring (2012) 34, (222-226)). Ther Drug Monit, 34(4), 485. (Read full article)
    51. Juenke JM, Miller KA, Ford MA, McMillin GA, Johnson-Davis KL (2011). A comparison of two FDA approved lamotrigine immunoassays with ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chim Acta, 412(19-20), 1879-82. (Read full article)
    52. Johnson-Davis KL, Fernelius C, Eliason NB, Wilson A, Beddhu S, Roberts WL (2011). Blood enzymes and oxidative stress in chronic kidney disease: a cross sectional study. Ann Clin Lab Sci, 41(4), 331-9. (Read full article)
    53. Rockwood AL, Johnson-Davis KL (2011). Mass spectrometry for clinical toxicology: therapeutic drug management and trace element analysis. Clin Lab Med, 31(3), 407-28. (Read full article)
    54. Johnson-Davis KL, De S, Jimenez E, McMillin GA, De BK (2011). Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method. Ther Drug Monit, 33(4), 453-9. (Read full article)
    55. Juenke JM, Wienhoff KA, Anderson BL, McMillin GA, Johnson-Davis KL (2011). Performance characteristics of the ARK diagnostics gabapentin immunoassay. Ther Drug Monit, 33(4), 398-401. (Read full article)
    56. Juenke JM, Miller KA, McMillin GA, Johnson-Davis KL (2011). An automated method for supporting busulfan therapeutic drug monitoring. Ther Drug Monit, 33(3), 315-20. (Read full article)
    57. Juenke JM, Brown PI, Johnson-Davis KL, McMillin GA (2011). Simultaneous quantification of levetiracetam and gabapentin in plasma by ultra-pressure liquid chromatography coupled with tandem mass spectrometry detection. Ther Drug Monit, 33(2), 209-13. (Read full article)
    58. Johnson-Davis KL, Moore SJ, Owen WE, Cutler JM, Frank EL (2009). A rapid HPLC method used to establish pediatric reference intervals for vitamins A and E. Clin Chim Acta, 405(1-2), 35-8. (Read full article)
    59. Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, Fleckenstein AE, Wilkins DG (2006). Persistence of tolerance to methamphetamine-induced monoamine deficits. Eur J Pharmacol, 559(1), 46-54. (Read full article)
    60. Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE (2005). Bupropion increases striatal vesicular monoamine transport. Neuropharmacology, 49(6), 820-30. (Read full article)
    61. Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE (2005). Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J Pharmacol Exp Ther, 314(3), 1087-92. (Read full article)
    62. Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins DG (2004). Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther, 309(2), 578-86. (Read full article)
    63. Johnson-Davis KL, Fleckenstein AE, Wilkins DG (2003). The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol, 482(1-3), 151-4. (Read full article)
    64. Johnson-Davis KL, Hanson GR, Keefe KA (2003). Lack of effect of kappa-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats. Neurotox Res, 5(4), 273-81. (Read full article)
    65. Johnson-Davis KL, Hanson GR, Keefe KA (2002). Long-term post-synaptic consequences of methamphetamine on preprotachykinin mRNA expression. J Neurochem, 82(6), 1472-9. (Read full article)

    Review

    1. Hubbard JA, Johnson-Davis KL (2024). Racism in Drug Testing. [Review]. Clin Lab Med, 44(4), 607-617. (Read full article)
    2. Neuman MG, Seitz HK, Teschke R, Malnick S, Johnson-Davis KL, Cohen LB, German A, Hohmann N, Moreira B, Moussa G, Opris M (2022). Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury. [Review]. Curr Issues Mol Biol, 44(3), 1294-1315. (Read full article)

    Book Chapter

    1. Johnson-Davis KL (2020). Cyanide toxicity—a case study. In Johnson-Davis KL (Ed.), Toxicology Cases for the Clinical and Forensic Laboratory (pp. 473-479). (Read full article)
    2. Maharjan AS, Johnson-Davis KL (2019). Issues of interferences with immunoassays used for screening of drugs of abuse in urine. In Maharjan AS|Johnson-Davis KL (Ed.), Critical Issues in Alcohol and Drugs of Abuse Testing (pp. 129-139). (Read full article)
    3. McMillin GA, Johnson-Davis KL (2019). Issues of interferences in therapeutic drug monitoring. In McMillin GA|Johnson-Davis KL (Ed.), Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction, Second Edition (pp. 215-231). (Read full article)
    4. Johnson-Davis KL, Dasgupta A (2016). Special Issues in Therapeutic Drug Monitoring in Patients With Uremia, Liver Disease, and in Critically Ill Patients. In Johnson-Davis KL|Dasgupta A (Ed.), Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics (pp. 245-260). (Read full article)
    5. Johnson-Davis KL, McMillin GA (2016). Application of Liquid Chromatography Combined with Mass Spectrometry or Tandem Mass Spectrometry for Therapeutic Drug Monitoring of Immunosuppressants. In Johnson-Davis KL|McMillin GA (Ed.), Personalized Immunosuppression in Transplantation: Role of Biomarker Monitoring and Therapeutic Drug Monitoring (pp. 57-81). (Read full article)
    6. Johnson-Davis K (2013). Enzymes. In Johnson-Davis K (Ed.), Clinical Chemistry: Principles, Techniques, and Correlations: Seventh Edition (pp. 262-291). (Read full article)
    7. McMillin G, Johnson-Davis K (2013). Issues of Interferences in Therapeutic Drug Monitoring. In McMillin G|Johnson-Davis K (Ed.), Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction (pp. 195-211). (Read full article)
    8. Johnson-Davis K, Fleckenstein A (2007). Methamphetamine. In Johnson-Davis K|Fleckenstein A (Ed.), xPharm: The Comprehensive Pharmacology Reference (pp. 1-7). (Read full article)

    Letter

    1. Juenke JM, McGraw JP, McMillin GA, Johnson-Davis KL (2012). Performance characteristics and patient comparison of the ARK Diagnostics levetiracetam immunoassay with an ultra-high performance liquid chromatography with tandem mass spectrometry detection method. [Letter to the editor]. Clin Chim Acta, (413(3-4)), 529-31.
    2. McMillin GA, Johnson-Davis KL (2011). In reply [Letter to the editor]. Clin Chem, 57(4), 644-645. (Read full article)
    3. Johnson-Davis KL, Thompson CD, Clark CJ, McMillin GA, Lehman CM (2010). High amphetamine/methamphetamine concentrations in urine can cause error codes on the ortho vitros® fusion 5,1 FS automated chemistry analyzer [Letter to the editor]. J Anal Toxicol, 34(9), 607-608. (Read full article)

    Other

    1. Bajaj AO, Kushnir MM, Kish-Trier E, McMillin GA, Johnson-Davis KL (2021). Automated separation and washing of red blood cells (RBCs) from whole blood. [ IP.com PCOM000264613D.].